Amgen, Synthon and Watson Pharmaceuticals in a biosimilar pact
11:25 EDT 19 Jul 2012 | Current Partnering
Synthon has entered into a global license agreement with Amgen  and Watson Pharmaceuticals, for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin, which is currently approved for treatment of breast cancer and gastric cancer. Under the agreement, Watson has acquired the license to the biosimilar program and has contributed it to the Amgen/Watson biosimilars [...]The post Amgen, Synthon and Watson Pharmaceuticals in a biosimilar pact appeared first on Current Partnering
Original Article: Amgen, Synthon and Watson Pharmaceuticals in a biosimilar pact
More From BioPortfolio on "Amgen, Synthon and Watson Pharmaceuticals in a biosimilar pact"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
